HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Givel, M. Search for Related Content PubMed PubMed Citation Articles by Givel, M.

FDA legislation

Correspondence to:
Dr Michael S Givel
Department of Political Science, University of Oklahoma, 455 West Lindsey, Room 205, Norman, OK 73019, USA; mgivel@ou.edu

Keywords: Food and Drug Administration legislation; regulatory policy; tobacco consumption

The first 150 words of the full text of this article appear below.

Since 2004, a highly unusual annual spectacle has occurred with the introduction in Congress of similar US Food and Drug Administration (FDA) tobacco regulation bills. Often accompanied by considerable controversy and animosities, these FDA tobacco bills have always been supported by the tobacco giant Philip Morris along with numerous health groups including the Campaign for Tobacco-Free Kids, American Heart Association, American Lung Association, and American Cancer Society. At the centre of this controversy have been two important policy issues and questions. Firstly, why would a giant tobacco company actually campaign to be more stringently regulated? Secondly, given the history of tobacco industry disease, deception, and duplicity why would anti-tobacco advocates actually believe that this is in the best interest of public health and even public health advocacy?

The origins of this modern controversy began in 1996 when the FDA issued a final rule regulating tobacco as a drug . . . [Full text of this article]